Skip to main content
. 2024 Sep 24;13(32):2401187. doi: 10.1002/adhm.202401187

Figure 6.

Figure 6

Effect of SYN321 in a rat MIA model of OA. A) A graphical representation of the experimental set‐up is reported. B) Animals’ body weight measured at the beginning of the study (day ‐1, baseline) and every 4 days, starting from day 11. Results are reported as percentage of the baseline. C) Results of the weight bearing tests, showing the weight‐bearing difference between the left (i.e. healthy) and right (i.e. where MIA was administered unilaterally) legs, measured at the beginning of the study (day ‐1, baseline) and on study days 10, 12, 14, 17, and then once weekly. Black arrows in both graphs indicate day 11, i.e. day of treatment administration. D) Results of the open‐field test, showing rats’ walking distance on day 10, 24 and 38. In each of these tests five groups were compared, i.e. receiving (i) saline solution (Group 1, in light blue), (ii) HA and diclofenac (Group 2, in grey), (iii) 0.5 mg per joint SYN321 (Group 3, in orange), (iv) 0.15 mg per joint SYN321 (Group 4, in red), (v) 0.05 mg per joint SYN321 (Group 5, in green).